References
- Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hematopoietic malignancies in India. Med Oncol 2002;19:141–150.
- Peggs K, Mackinnnon S. Imatinib mesylate - new gold standard for treatment of chronic myeloid leukemia. N Eng J Med 2003;348:1048–1050.
- Talpaz M, Kantarjian HM, McCredie KB, et al Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986;314:1065–1069.
- Kumar L. Chronic myelogenous leukemia (CML): an update. Natl Med J India 2006;19:255–263.
- Available from: http://webapps.ctcp.nci.nih.gov/webobjs/ctc/webhelp/ctcv2.htm
- O'Brien S, Kantarjian H, Keating M, et al Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322–3326.
- Rodrigues J, Cortes J, Smith T, et al Determination of prognosis in late chronic phase CML. J Clin Oncol 1998;16:3782–3787.
- Kantarjian HM, Cortes JE, O'Brien S, et al Long term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome positive chronic phase chronic myeloid leukemia after failure of interferon alpha. Blood 2004;104:1979–1988.
- Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R. Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country. Leuk Lymphoma 2008;49:554–558.
- Hochhaus A, Druker B, Sawyer C, et al Favourable long-term follow up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha treatment. Blood 2008;111:1039–1043.
- Hochhaus A, O'Brien SG, Guilhot F, et al Six year follow up of patients receiving imatinib for the first line treatment of CML. Leukemia 2009;23:1054–1061.